BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32431503)

  • 21. Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.
    Penning TM
    Expert Opin Ther Pat; 2017 Dec; 27(12):1329-1340. PubMed ID: 28895472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The AKR1C3/AR-V7 complex maintains CRPC tumour growth by repressing B4GALT1 expression.
    Wang B; Wu S; Fang Y; Sun G; He D; Hsieh JT; Wang X; Zeng H; Wu K
    J Cell Mol Med; 2020 Oct; 24(20):12032-12043. PubMed ID: 32902124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion.
    Kaipainen A; Zhang A; Gil da Costa RM; Lucas J; Marck B; Matsumoto AM; Morrissey C; True LD; Mostaghel EA; Nelson PS
    Prostate; 2019 Sep; 79(13):1530-1542. PubMed ID: 31376206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pomegranate extracts impact the androgen biosynthesis pathways in prostate cancer models in vitro and in vivo.
    Ming DS; Pham S; Deb S; Chin MY; Kharmate G; Adomat H; Beheshti EH; Locke J; Guns ET
    J Steroid Biochem Mol Biol; 2014 Sep; 143():19-28. PubMed ID: 24565566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.
    Adeniji AO; Twenter BM; Byrns MC; Jin Y; Chen M; Winkler JD; Penning TM
    J Med Chem; 2012 Mar; 55(5):2311-23. PubMed ID: 22263837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
    Zhao J; Zhang M; Liu J; Liu Z; Shen P; Nie L; Guo W; Cai D; Liu J; Armstrong CM; Sun G; Chen J; Zhu S; Dai J; Zhang H; Zhao P; Zhang X; Yin X; Zhu X; Ni Y; Chen N; Zeng H
    Prostate; 2019 Sep; 79(13):1553-1562. PubMed ID: 31294486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
    Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
    Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.
    Yang JC; Xu P; Ning S; Wasielewski LJ; Adomat H; Hwang SH; Morisseau C; Gleave M; Corey E; Gao AC; Lara PN; Evans CP; Hammock BD; Liu C
    Oncogene; 2023 Feb; 42(9):693-707. PubMed ID: 36596844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer.
    Mostaghel EA; Zhang A; Hernandez S; Marck BT; Zhang X; Tamae D; Biehl HE; Tretiakova M; Bartlett J; Burns J; Dumpit R; Ang L; Matsumoto AM; Penning TM; Balk SP; Morrissey C; Corey E; True LD; Nelson PS
    Clin Cancer Res; 2019 Jan; 25(1):426-439. PubMed ID: 30181386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M; Huang Y; Ratnam M
    Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer.
    Toren P; Kim S; Johnson F; Zoubeidi A
    PLoS One; 2016; 11(4):e0152861. PubMed ID: 27046225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin-6 regulates androgen synthesis in prostate cancer cells.
    Chun JY; Nadiminty N; Dutt S; Lou W; Yang JC; Kung HJ; Evans CP; Gao AC
    Clin Cancer Res; 2009 Aug; 15(15):4815-22. PubMed ID: 19638459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
    Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
    Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3).
    Kikuchi A; Furutani T; Azami H; Watanabe K; Niimi T; Kamiyama Y; Kuromitsu S; Baskin-Bey E; Heeringa M; Ouatas T; Enjo K
    Invest New Drugs; 2014 Oct; 32(5):860-70. PubMed ID: 24981575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Downregulation of androgen receptors by NaAsO
    Kim Y; Park SE; Moon JW; Kim BM; Kim HG; Jeong IG; Yoo S; Ahn JB; You D; Pak JH; Kim S; Hwang JJ; Kim CS
    Prostate; 2017 Jul; 77(10):1128-1136. PubMed ID: 28556958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer.
    Singh KB; Ji X; Singh SV
    Mol Cancer Ther; 2018 Oct; 17(10):2079-2090. PubMed ID: 30030299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor.
    Adeniji A; Uddin MJ; Zang T; Tamae D; Wangtrakuldee P; Marnett LJ; Penning TM
    J Med Chem; 2016 Aug; 59(16):7431-44. PubMed ID: 27486833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.
    Liu C; Lou W; Zhu Y; Yang JC; Nadiminty N; Gaikwad NW; Evans CP; Gao AC
    Cancer Res; 2015 Apr; 75(7):1413-22. PubMed ID: 25649766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis.
    Hagberg Thulin M; Nilsson ME; Thulin P; Céraline J; Ohlsson C; Damber JE; Welén K
    Mol Cell Endocrinol; 2016 Feb; 422():182-191. PubMed ID: 26586211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.